Unlock Premium Data: Up to 50% Off InvestingProCLAIM SALE

Johnson & Johnson To Acquire Early-Stage Eczema Treatment Developer Proteologix For $850M

Published 16/05/2024, 17:35
© Reuters.  Johnson & Johnson To Acquire Early-Stage Eczema Treatment Developer Proteologix For $850M

Benzinga - by Vandana Singh, Benzinga Editor.

Thursday, Johnson & Johnson (NYSE:JNJ) agreed to acquire Proteologix Inc., a privately held biotechnology company focused on bispecific antibodies for immune-mediated diseases, for $850 million in cash, with the potential for an additional milestone payment.

Proteologix’s portfolio includes:

  • PX128, a bispecific antibody targeting IL-13 plus TSLP, which is ready to enter phase 1 development for moderate to severe atopic dermatitis (AD) and moderate to severe asthma.
  • PX130, a bispecific antibody targeting IL-13 plus IL-22, which is in preclinical development for moderate to severe AD.
PX128 inhibits IL-13-mediated Th2 skin inflammation, an important disease-driving pathway in­ AD and asthma, and TSLP, a mediator of tissue inflammation in AD and asthma.

Like PX128, PX130 inhibits IL-13-mediated Th2 skin inflammation.

PX130 also inhibits IL-22 to restore the skin barrier and prevent inflammation from environmental triggers, such as allergens.

Both assets are designed for infrequent dosing intervals.

“We see an opportunity for best-in-disease efficacy for both PX128 and PX130 as each bispecific antibody targets two different combinations of disease-driving pathways that are mediating the skin inflammation in heterogenous subpopulations of AD patients,” said David Lee, Global Immunology Therapeutic Area Head, Johnson & Johnson Innovative Medicine

In addition to PX128 and PX130, the acquisition will provide J&J with other bispecific antibody programs with applications across various other diseases, further boosting the company’s capabilities to create novel bispecific programs.

Atopic dermatitis (AD), also known as eczema, is a chronic inflammatory skin disorder that affects more than 102.8 million children and 101.3 million adults worldwide.

Recently, Johnson & Johnson agreed to acquire Shockwave Medical Inc. (NASDAQ:SWAV) for $335 per share in cash, corresponding to an enterprise value of approximately $13.1 billion, including the cash acquired.

Price Action: JNJ shares are up 0.53% at $153.48 at last check Thursday.

Photo via Shutterstock

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.